Skip to main content
Log in

Omalizumab for the treatment of solar urticaria: many questions remain unresolved

  • Letter to the editors
  • Published:
Allergo Journal International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101–9

    Article  CAS  PubMed  Google Scholar 

  2. Kowalzick L, Eickenscheidt L, Pfeiffer AK, Pönnighaus JM, Surber C. Erfolgreiche multimodale Therapie der Licht-Urtikaria. Akt Dermatol 2013;39:83–6

    Article  Google Scholar 

  3. Güzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with anti-immunglobulin E therapy. Allergy 2008;63:1563–5

    Article  PubMed  Google Scholar 

  4. Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010;125:490–1

    Article  CAS  PubMed  Google Scholar 

  5. Duchini G, Bäumler W, Bircher AJ, Scherer K. Failure of omalizumab (Xolair®) in the treatment of solar urticaria caused by ultraviolett A and visible light. Photodermatol Photoimmunol Photomed 2011;27:336–7

    Article  CAS  PubMed  Google Scholar 

  6. Müller S, Schempp CM, Jakob T. Failure of omalizumab in the treatment of solar urticaria. J Eur Acad Dermatol Venereol 2016; 30:524–5

    Article  PubMed  Google Scholar 

  7. Baliu-Piqué C, Aguilera Peiró P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol 2016;30:704–6

    Article  PubMed  Google Scholar 

  8. Arasi S, Crisafulli G, Caminiti L, Guarneri F, Aversa T, Porcaro F et al. Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria. Pediatr Allergy Immunol 2015;26:583–5

    Article  PubMed  Google Scholar 

  9. Levi A, Tal Y, Dranitzki Z, Shalit M, Enk CD. Successful omalizumab treatment of severe solar urticaria in a 6-year-old child. Pediatr Allergy Immunol 2015;26:588–90

    Article  CAS  PubMed  Google Scholar 

  10. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticarial: a retrospective clinical analysis. J Derm Sci 2014;73:57–62

    Article  CAS  Google Scholar 

  11. Metz M, Altrichter S, Ardelan E, Keßler B, Krause K, Magerl M et al. Anti-immunglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011,154:177–80

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lutz Kowalzick.

Additional information

Conflict of interest

Prof. Dr. Kowalzick is a clinical investigator for Novartis Pharma.

Cite this as

Kowalzick L. Omalizumab for the treatment of solar urticaria: many questions remain unresolved. Allergo J Int 2016;25:96–7 DOI: 10.1007/s40629-016-0111-7

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kowalzick, L. Omalizumab for the treatment of solar urticaria: many questions remain unresolved. Allergo J Int 25, 96–97 (2016). https://doi.org/10.1007/s40629-016-0114-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40629-016-0114-4

Key words

Navigation